Official announcement! Five Chinese pharmaceutical companies entered Pfizer covid-19 list of “special imitation” oral drugs

The Geneva medicines patent pool (MPP) announced that Shanghai Desano, Zhe Jiang Hua Hai Pharmaceuticalco.Ltd(600521) ( Zhe Jiang Hua Hai Pharmaceuticalco.Ltd(600521) . SH), Apeloa Pharmaceutical Co.Ltd(000739) ( Apeloa Pharmaceutical Co.Ltd(000739) . SZ), Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) ( Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) . SH), Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) ( Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) . SH), five Chinese pharmaceutical enterprises, have entered the “special imitation” list of Pfizer covid-19 oral drug paxlovid. During the covid-19 epidemic is still defined as a public health emergency, they can produce nimatrilvir, the core component of paxlovid, free of patent fee. The Geneva pharmaceutical patent pool press release said the agreement would help supply covid-19 drugs to about 53% of the world’s population. Among the five Chinese pharmaceutical enterprises, Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) only produces APIs, and the other four can produce APIs and preparations at the same time.